-

Agilent 2024 Early Career Professor Award Presented to Adeyemi Adeleye

Columbia University scientist recognized for his contributions to sustainability and improving environmental health

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Adeyemi Adeleye, Ph.D., has received the Agilent 2024 Early Career Professor Award for his contribution to environmental health and sustainability, developing green analytical technologies, methods, or laboratory working environments. Dr. Adeleye is an assistant professor in the Department of Earth and Environmental Engineering at Columbia University.

The 2024 award focused on contributions to academic research in sustainability and green chemistry. Dr. Adeleye’s research focuses on improving environmental health and sustainability through green approaches, and specifically, using engineered nanoparticles made of earth-abundant, essential elements such as iron, sulfur, and silicon to remediate environmental matrices contaminated with persistent pollutants like arsenic, lead, and per- and polyfluoroalkyl substances (PFAS). Additionally, Dr. Adeleye is studying ways to combine remediation with carbon sequestration in soil to reduce the environmental impact of these approaches.

“I am deeply honored and grateful to receive this esteemed award, which recognizes my research group’s efforts and inspires us to continue striving for excellence,” said Dr. Adeleye. “Persistent environmental contaminants, like heavy metals, pose a significant threat to food safety and human health. "We will continue to expand our understanding of how heavy metals interact with engineered surfaces in natural environments, supporting our long-term goal of developing sustainable solutions to heavy metal contamination. The support from Agilent will undoubtedly help us achieve this important ambition.”

“Agilent is committed to advancing environmental sustainability and empowering innovation that accelerates the development of eco-friendly solutions by supporting researchers who are pioneering green analytical technologies and sustainable laboratory practices,” said Nahid Chalyavi, associate vice president of University Relations and External Research at Agilent. “This year’s award recipient, Dr. Adeleye, is at the forefront of integrating environmental chemistry, engineering, and material science. His research focuses on understanding the reactions between pollutants and reactive surfaces in environmental systems and applying this knowledge to remediate polluted environments.”

Dr. Adeleye’s research supports the effort of the US Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) to tackle the widespread occurrence of toxic heavy metals in crop-based foods through the “Closer-to-Zero” Initiative. The National Science Foundation (NSF) and the Centers for Disease Control and Prevention (CDC) have also supported his work.

The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the program is available at Agilent.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From AGILENT TECHNOLOGIES INC

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website...

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...
Back to Newsroom